Evolus, Inc. (EOLS) stock

EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30

$6.96−0.22 (-3.06%)

Close on Nov 13, 2026Market cap $459.71MP/E –Yield –

Evolus EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Evolus has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is EOLS.

Revenue growth13.9% · median 21.0%

Gross margin66.4% · median 90.1%

Operating margin-4.8% · median 6.9%

Net margin-9.6% · median 5.9%

Advertisement
300 × 250

See a number that looks wrong?